Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04278651
Other study ID # 19G.929
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 29, 2021
Est. completion date December 30, 2025

Study information

Verified date April 2024
Source Thomas Jefferson University
Contact Rupsa C Boelig, MD
Phone 215-955-9196
Email rupsa.boelig@jefferson.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, controlled multi-site trial of iron therapy in pregnancy. The purpose of this research is to see if second trimester initiation of intravenous (IV) iron therapy is better than oral iron therapy for treatment of anemia in pregnancy by improving blood count, quality of life and reducing side effects.


Description:

Pregnant singletons diagnosed with iron deficiency anemia will be enrolled between 14-24 weeks and will be randomized 1:1 to either a course of ferumoxytol (510mg x 2 doses 3-8 days apart) or oral iron (325mg) twice daily.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 30, 2025
Est. primary completion date August 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Singleton gestation - Gestational age <24 weeks - Baseline Hb =9.0 and <11.0 with evidence of iron deficiency anemia Iron deficiency anemia diagnosed (at any point in patient history) by: - Hb<11.0 - Ferritin<30 and/or total iron saturation <20 Exclusion Criteria: - Sickle cell Disease (NOT sickle cell trait) - Evidence of acute anemia requiring transfusion or IV iron therapy - Major congenital or chromosomal anomaly - Previous use of IV iron in this pregnancy - Severe cardiac, renal, or liver disease - Autoimmune disease (ie Systemic Lupus Erythematosus (SLE) - Allergy or contraindication to either study drug - History of medication allergy, reaction to IV infusion, or reaction to Feraheme or other IV iron products

Study Design


Intervention

Drug:
Ferumoxytol
510mg infusion x 2 doses 3-8 days apart
Ferrous Sulfate
325mg oral twice daily

Locations

Country Name City State
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Thomas Jefferson University Auerbach Hematology and Oncology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Hemoglobin Change in hemoglboin at day 90 following treatment initiation 90 days
Secondary Anemia resolution Percent of participants in each group with Hb>=11.0 at day 90 90 days
Secondary Anemia at Delivery Percent of participants in each group with Hb>=11.0 at delivery 9 months
Secondary Need for additional therapy Percent of participants in each group requiring additional therapy for iron deficiency anemia after 28 weeks 9 months
Secondary Quality of life scale Linear Analogue Scale Assessment 30, 60, 90 days
Secondary Adherence adherence to assigned group. Measured by what % of IV infusions completed of the two required in IV iron group, and for oral iron group, what %pills taken/prescribed based on pill counts 90 days
Secondary Need for post partum transfusion Incidence of transfusion after delivery/post partum 9 months
Secondary Neonatal outcomes: cord blood iron indices Hb, ferritin, total iron saturation 9 months
Secondary Neonatal outcomes: birth weight birth weight (grams) 9 months
Secondary Neonatal outcomes gestational age of delivery (weeks) gestational age of delivery (weeks) 9 months
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT04960800 - Effect of a Specific Exercise Program During Pregnancy on Diastasis Recti Abdominis N/A